Loading
Zomedica Corp. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Klass Russell Kevin, was filed 14 Nov 2025.
Zomedica Corp.: what insiders have been doing
This page follows insider dealings at Zomedica Corp. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. The last twelve months, up to 22 October 2026, brought 4 filings signed by 1 insider.
Only purchases show up on the open market, 4 purchases in all worth €41k, filed by 1 insider. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The largest single trade was a purchase of €18k by Klass Russell Kevin, published on 7 November 2025. The buyers include 1 senior executive.
With 4 filings in twelve months, the company is quieter than the median of 8 filings across the 277 companies we follow on the same exchange. Over the whole record (from 2021), the tally stands at 61 purchases and 13 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists net income at -81.9 m USD.
The clock since the last published purchase (14 November 2025) now reads 344 days. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4.
Other companies in the same sector with recent insider buying flagged by our signals: Xenon Pharmaceuticals Inc. and Vivos Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
91
Thresholds
n/a
Buy Volume
€937,258
61 ops. · all time
Sell Volume
€4M
13 ops. · all time
Who traded when
BuySaleRussell Kevin Klass13 buys
Johnny D. Powers7 buys
Jeffrey M. Rowe6 buys
Larry C. Heaton II5 buys
Anthony K. Blair4 buys
Christopher Ross Macleod1 buy
+3 other insiders
Since the insiders bought
- +45.2%Entry US$0.09 · Close at T+90 US$0.14
- +112.2%Entry US$0.05 · Close at T+365 US$0.10
- +123.4%Entry US$0.05 · Close at T+365 US$0.10
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 22,035 of 26,289 companies
27.6
score / 100
Value5
Quality50
FCF yld-24%
Earn yld-106%
EV/EBITDA·
ROE-16%
Gross mgn68%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.08
Analyst consensus
Income statement
RevenueUS$32M
Gross profitUS$21.7M68% margin
EBITDA-US$20.6M-64% margin
Net income-US$81.9M-51.4% margin
Valuation
P/Book0.7x
Beta1.33
Balance sheet & cash
Market capUS$77.4M
Total debtUS$2.2M
Free Cash Flow-US$18.6M
Debt / Equity2%
Profitability & ownership
ROE-16.3%
ROA-10.2%
% insiders2.7%
% institutions0.0%
Last declaration on 14 November 2025
Declarations91 total
150,000 shares@ US$0.0976.0% of flowCommon Stock, without par valueSEC:0001654954-25-013020:0
Canonical exit: 11 Feb 2026 (T+90)
120,000 shares@ US$0.0984.9% of flowCommon Stock, without par value.SEC:0001654954-25-012794:0
Canonical exit: 8 Feb 2026 (T+90)
5,000 shares@ US$0.0950.2% of flowCommon Stock, without par valueSEC:0001654954-25-012783:0
Canonical exit: 5 Feb 2026 (T+90)
253,007 shares@ US$0.088.5% of flowCommon Stock, without par valueSEC:0001654954-25-012706:0
Canonical exit: 4 Feb 2026 (T+90)
250,000 shares@ US$0.042.4% of flowCommon Stock, without par valueSEC:0001654954-25-009503:1
Canonical exit: 10 Nov 2025 (T+90)
745,341 shares@ US$0.047.2% of flowCommon Stock, without par valueSEC:0001654954-25-009503:2
Canonical exit: 10 Nov 2025 (T+90)
60,723 shares@ US$0.041.0% of flowCommon Stock, without par valueSEC:0001654954-25-009503:0
Canonical exit: 9 Nov 2025 (T+90)
250,000 shares@ US$0.042.4% of flowCommon Stock, without par valueSEC:0001654954-25-009402:1
Canonical exit: 9 Nov 2025 (T+90)
500,000 shares@ US$0.048.3% of flowCommon Stock, without par valueSEC:0001654954-25-009400:0
Canonical exit: 6 Nov 2025 (T+90)
250,000 shares@ US$0.0383.9% of flowCommon Stock, without par valueSEC:0001654954-25-009402:0
Canonical exit: 9 Nov 2025 (T+90)
63,750 shares@ US$0.053.5% of flowCommon Stock, without par valueSEC:0001654954-25-006001:1
Canonical exit: 19 Aug 2025 (T+90)
36,250 shares@ US$0.0492.0% of flowCommon Stock, without par valueSEC:0001654954-25-006001:0
Canonical exit: 19 Aug 2025 (T+90)
500,000 shares@ US$0.0466.8% of flowCommon Stock, without par valueSEC:0001654954-25-005943:0
Canonical exit: 17 Aug 2025 (T+90)
104,300 shares@ US$0.048100.0% of flowCommon Stock, without par valueSEC:0001654954-25-005944:0
Canonical exit: 17 Aug 2025 (T+90)
300,000 shares@ US$0.062100.0% of flowCommon Stock, without par valueSEC:0001654954-25-003016:0
Canonical exit: 15 Jun 2025 (T+90)
118,855 shares@ US$0.0586.6% of flowCommon Stock, without par valueSEC:0001654954-25-002960:1
Canonical exit: 15 Jun 2025 (T+90)
191,817 shares@ US$0.0611.0% of flowCommon Stock, without par valueSEC:0001654954-25-002960:2
Canonical exit: 15 Jun 2025 (T+90)
179,328 shares@ US$0.0610.3% of flowCommon Stock, without par valueSEC:0001654954-25-002960:3
Canonical exit: 15 Jun 2025 (T+90)
50,000 shares@ US$0.070.3% of flowCommon Stock, without par valueSEC:0001654954-25-002963:1
Canonical exit: 15 Jun 2025 (T+90)
100,000 shares@ US$0.0670.5% of flowCommon Stock, without par valueSEC:0001654954-25-002963:2
Canonical exit: 15 Jun 2025 (T+90)
50,000 shares@ US$0.0670.3% of flowCommon Stock, without par valueSEC:0001654954-25-002963:4
Canonical exit: 15 Jun 2025 (T+90)
100,000 shares@ US$0.0650.5% of flowCommon Stock, without par valueSEC:0001654954-25-002963:5
Canonical exit: 15 Jun 2025 (T+90)
100,647 shares@ US$0.077.3% of flowCommon Stock, without par valueSEC:0001654954-25-002968:1
Canonical exit: 15 Jun 2025 (T+90)
68,000 shares@ US$0.0674.7% of flowCommon Stock, without par valueSEC:0001654954-25-002968:2
Canonical exit: 15 Jun 2025 (T+90)
731,368 shares@ US$0.06851.8% of flowCommon Stock, without par valueSEC:0001654954-25-002968:3
Canonical exit: 15 Jun 2025 (T+90)
25 of 91 declarations
About Zomedica Corp.
Zomedica Corp. is a U.S.-based animal health company focused on veterinary therapeutics and diagnostics. It is currently quoted on the OTCQB under the ticker ZOMDF, and historically has also been associated with the NYSE American market. The company is headquartered in Ann Arbor, Michigan, United States, and was founded in 2015. From an international equity analyst’s perspective, Zomedica is best viewed as a niche animal-health platform targeting veterinarians serving companion animals and horses, with an emphasis on products that can improve both clinical outcomes and practice economics.
The company’s business model centers on a portfolio of veterinary devices and diagnostic systems. Its flagship product, PulseVet®, is a shock-wave therapy system used to accelerate healing in musculoskeletal conditions. Zomedica also markets the Assisi® line of therapeutic devices, the TRUFORMA® point-of-care diagnostic platform, the TRUVIEW® digital cytology system, and VetGuardian®, a no-touch monitoring solution. This mix gives the company exposure to multiple revenue drivers: capital equipment, consumables, and broader practice workflow adoption. For veterinarians, the value proposition is straightforward—faster diagnosis, differentiated treatment tools, and solutions designed to improve patient care while supporting clinic efficiency.
Read moreShow less
Competitively, Zomedica operates in a fragmented but highly competitive animal-health market. It is not a scale leader in the global sense; instead, its investment case rests on product innovation, targeted clinical use cases, and the ability to integrate acquired assets into a coherent commercial strategy. Management has highlighted an addressable U.S. market of more than $2 billion across its product set, which signals a meaningful opportunity, but also underscores the level of competition from larger, better-capitalized animal-health companies. As a result, execution quality, sales-force effectiveness, and product adoption trends are central to the stock’s long-term outlook.
Geographically, Zomedica’s corporate headquarters are in Ann Arbor, Michigan, and the company manufactures and distributes from facilities in Michigan, Georgia, and Minnesota. It has also discussed Assisi-related distribution operations in New Jersey, which it has been transitioning toward its other facilities. Recent company updates point to ongoing commercial expansion, international growth efforts, and improved operating scale. Zomedica also reported revenue growth in 2025 in its investor materials, while still remaining unprofitable and continuing to invest in R&D, commercialization, and infrastructure. That combination makes the company a classic small-cap growth story: potentially attractive upside if adoption continues, but with clear operational and financial risks. For market context, it is a U.S.-listed name, presently traded on OTCQB under ZOMDF, and previously linked to NYSE American.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
